<p>新泽西州伊瑟林，2026 年 1 月 6 日（全球新闻稿）——Outlook Therapeutics, Inc.（纳斯达克：OTLK），一家专注于提升贝伐单抗在视网膜疾病治疗中的标准护理的生物制药公司，今天宣布任命劳拉·坎特雷尔（Laura Cantrell）为企业战略与业务发展副总裁。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/f664cc57-e281-4cc3-a237-5e19e88648ea/laura-cantrell.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/f664cc57-e281-4cc3-a237-5e19e88648ea/laura-cantrell.jpg"/></p>
<p>“在我们发展过程中的关键时刻，我们非常高兴地欢迎劳拉加入 Outlook Therapeutics，” 首席执行官鲍勃·贾尔（Bob Jahr）表示。“劳拉在全球生物技术领域拥有二十年的经验，涵盖企业战略、业务发展和投资组合领导，她在识别、评估和执行高价值机会方面的卓越能力，将对我们推进使命、提供差异化的贝伐单抗眼科制剂以及追求最大化长期股东价值的机会至关重要。”</p>
<p>作为企业战略与业务发展副总裁，坎特雷尔女士将负责领导 Outlook Therapeutics 的业务发展战略，包括战略合作伙伴关系、许可机会和企业发展计划。</p>
<p>“我很高兴能加入 Outlook Therapeutics，并在公司如此重要的时刻与领导团队一起工作，” 新任企业战略与业务发展副总裁劳拉·坎特雷尔表示。“我期待利用我在业务发展、全球合作伙伴关系和投资组合战略方面的经验，帮助推进公司的项目，探索战略机会，并支持 Outlook 的下一个增长阶段。”</p>
<p>坎特雷尔女士在全球企业战略、业务发展和投资组合领导方面拥有超过 20 年的经验，是一位经验丰富的生物技术高管，深谙业务发展、商业战略和全球投资组合扩展。她曾在多家领先的生物技术公司担任高级领导职务，包括 Medivation（被辉瑞收购）、百济神州、索比、Axovant Sciences 和基因泰克/罗氏。在她的职业生涯中，她领导了高影响力的许可、收购和合作伙伴关系计划，包括作为支持 Medivation 以 140 亿美元被辉瑞收购的核心团队成员，以及支持收购 TALZENNA 的商业评估。坎特雷尔女士在推动生物制剂和肿瘤资产的全球商业化战略和生命周期管理方面拥有丰富的经验，包括贝伐单抗，并领导负责北美、欧洲和国际市场的产品发布和监管批准的资产团队。坎特雷尔女士拥有埃默里大学的 MBA 学位和密歇根大学的生物学学士学位。</p>
<p><strong>关于 Outlook Therapeutics, Inc.</strong></p>
<p>Outlook Therapeutics 是一家生物制药公司，专注于 ONS-5010/LYTENAVA™（贝伐单抗-vikg，贝伐单抗 gamma）的开发和商业化，以提升贝伐单抗在视网膜疾病治疗中的标准护理。LYTENAVA™（贝伐单抗 gamma）是首个获得欧洲委员会和 MHRA 市场授权用于治疗湿性 AMD 的贝伐单抗眼科制剂。Outlook Therapeutics 已在德国和英国开始 LYTENAVA™（贝伐单抗 gamma）的商业发布，作为湿性 AMD 的治疗。</p>
<p>在美国，ONS-5010/LYTENAVA™（贝伐单抗-vikg）仍处于研究阶段。如果在美国获得批准，ONS-5010/LYTENAVA™将成为首个获批用于视网膜适应症（包括湿性 AMD）的贝伐单抗眼科制剂。</p>
<p><strong>投资者咨询：</strong> 珍妮·托马斯（Jenene Thomas）</p>
<p>首席执行官</p>
<p>JTC Team, LLC</p>
<p>电话：908.824.0775</p>
<p>OTLK@jtcir.com</p>
<p>与本公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/f664cc57-e281-4cc3-a237-5e19e88648ea 获取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ESTVNU00zTXpRMU56WXdJekl3TWpnNE1qST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ESTVNU00zTXpRMU56WXdJekl3TWpnNE1qST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTMzYTdmNWEtMjVkNi00ZDE1LThhOGUtYTYyMzhkOGZiNWRjLTEwNDAzOTMtMjAyNi0wMS0wNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTMzYTdmNWEtMjVkNi00ZDE1LThhOGUtYTYyMzhkOGZiNWRjLTEwNDAzOTMtMjAyNi0wMS0wNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png"/></p>

OTLK

<p>Outlook Therapeutics, Inc. 任命 Laura Cantrell 为企业战略与业务发展副总裁。Cantrell 拥有超过 20 年的生物技术经验，将负责公司的业务发展战略，专注于合作伙伴关系和许可机会。首席执行官 Bob Jahr 对她提升股东价值和推进公司开发用于治疗视网膜疾病的贝伐单抗眼科制剂的能力表示信心。Outlook Therapeutics 目前正在德国和英国推出 LYTENAVA™，并在美国进行持续的研究</p>

<p>ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.</p>
<div class="lb-trans"><p>新泽西州伊瑟林，2026 年 1 月 6 日（全球新闻稿）——Outlook Therapeutics, Inc.（纳斯达克：OTLK），一家专注于提升贝伐单抗在视网膜疾病治疗中的标准护理的生物制药公司，今天宣布任命劳拉·坎特雷尔（Laura Cantrell）为企业战略与业务发展副总裁。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/f664cc57-e281-4cc3-a237-5e19e88648ea/laura-cantrell.jpg" alt="" original-src="https://ml.globenewswire.com/Resource/Download/f664cc57-e281-4cc3-a237-5e19e88648ea/laura-cantrell.jpg"/></p>
<p>“We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.”</p>
<div class="lb-trans"><p>“在我们发展过程中的关键时刻，我们非常高兴地欢迎劳拉加入 Outlook Therapeutics，” 首席执行官鲍勃·贾尔（Bob Jahr）表示。“劳拉在全球生物技术领域拥有二十年的经验，涵盖企业战略、业务发展和投资组合领导，她在识别、评估和执行高价值机会方面的卓越能力，将对我们推进使命、提供差异化的贝伐单抗眼科制剂以及追求最大化长期股东价值的机会至关重要。”</p>
</div><p>In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be responsible for leading Outlook Therapeutics’ business development strategy, including strategic partnerships, licensing opportunities and corporate development initiatives.</p>
<div class="lb-trans"><p>作为企业战略与业务发展副总裁，坎特雷尔女士将负责领导 Outlook Therapeutics 的业务发展战略，包括战略合作伙伴关系、许可机会和企业发展计划。</p>
</div><p>“I am excited to join Outlook Therapeutics and to work alongside the leadership team at such an important moment for the Company,” said Laura Cantrell, newly appointed Vice President of Corporate Strategy and Business Development. “I look forward to leveraging my experience in business development, global partnerships and portfolio strategy to help advance the company’s programs, explore strategic opportunities and support Outlook’s next phase of growth.”</p>
<div class="lb-trans"><p>“我很高兴能加入 Outlook Therapeutics，并在公司如此重要的时刻与领导团队一起工作，” 新任企业战略与业务发展副总裁劳拉·坎特雷尔表示。“我期待利用我在业务发展、全球合作伙伴关系和投资组合战略方面的经验，帮助推进公司的项目，探索战略机会，并支持 Outlook 的下一个增长阶段。”</p>
</div><p>Ms. Cantrell brings more than 20 years of experience in global corporate strategy, business development, and portfolio leadership across the biotechnology and pharmaceutical industries and is a seasoned biotech executive with deep expertise in business development, commercial strategy, and global portfolio expansion. She has held senior leadership roles at leading biotechnology companies, including Medivation (acquired by Pfizer), BeiGene, Sobi, Axovant Sciences, and Genentech/Roche. During her career, she has led high-impact licensing, acquisition, and partnership initiatives, including serving as a core member of the team that supported Medivation’s $14 billion acquisition by Pfizer and the commercial assessment supporting the acquisition of TALZENNA. Ms. Cantrell has extensive experience driving global commercialization strategies and lifecycle management for biologics and oncology assets, including bevacizumab, and has led asset teams responsible for launches and regulatory approvals across North America, Europe, and international markets. Ms. Cantrell holds an MBA from Emory University and a Bachelor of Science in Biology from the University of Michigan.</p>
<div class="lb-trans"><p>坎特雷尔女士在全球企业战略、业务发展和投资组合领导方面拥有超过 20 年的经验，是一位经验丰富的生物技术高管，深谙业务发展、商业战略和全球投资组合扩展。她曾在多家领先的生物技术公司担任高级领导职务，包括 Medivation（被辉瑞收购）、百济神州、索比、Axovant Sciences 和基因泰克/罗氏。在她的职业生涯中，她领导了高影响力的许可、收购和合作伙伴关系计划，包括作为支持 Medivation 以 140 亿美元被辉瑞收购的核心团队成员，以及支持收购 TALZENNA 的商业评估。坎特雷尔女士在推动生物制剂和肿瘤资产的全球商业化战略和生命周期管理方面拥有丰富的经验，包括贝伐单抗，并领导负责北美、欧洲和国际市场的产品发布和监管批准的资产团队。坎特雷尔女士拥有埃默里大学的 MBA 学位和密歇根大学的生物学学士学位。</p>
</div><p><strong>About Outlook Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Outlook Therapeutics, Inc.</strong></p>
</div><p>Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics has commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.</p>
<div class="lb-trans"><p>Outlook Therapeutics 是一家生物制药公司，专注于 ONS-5010/LYTENAVA™（贝伐单抗-vikg，贝伐单抗 gamma）的开发和商业化，以提升贝伐单抗在视网膜疾病治疗中的标准护理。LYTENAVA™（贝伐单抗 gamma）是首个获得欧洲委员会和 MHRA 市场授权用于治疗湿性 AMD 的贝伐单抗眼科制剂。Outlook Therapeutics 已在德国和英国开始 LYTENAVA™（贝伐单抗 gamma）的商业发布，作为湿性 AMD 的治疗。</p>
</div><p>In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.</p>
<div class="lb-trans"><p>在美国，ONS-5010/LYTENAVA™（贝伐单抗-vikg）仍处于研究阶段。如果在美国获得批准，ONS-5010/LYTENAVA™将成为首个获批用于视网膜适应症（包括湿性 AMD）的贝伐单抗眼科制剂。</p>
</div><p><strong>Investor Inquiries:</strong> Jenene Thomas</p>
<div class="lb-trans"><p><strong>投资者咨询：</strong> 珍妮·托马斯（Jenene Thomas）</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>T: 908.824.0775</p>
<div class="lb-trans"><p>电话：908.824.0775</p>
</div><p>OTLK@jtcir.com</p>
<div class="lb-trans"><p>OTLK@jtcir.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f664cc57-e281-4cc3-a237-5e19e88648ea</p>
<div class="lb-trans"><p>与本公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/f664cc57-e281-4cc3-a237-5e19e88648ea 获取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ESTVNU00zTXpRMU56WXdJekl3TWpnNE1qST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMDI5MSM3MzQ1NzYwIzIwMjg4MjI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTMzYTdmNWEtMjVkNi00ZDE1LThhOGUtYTYyMzhkOGZiNWRjLTEwNDAzOTMtMjAyNi0wMS0wNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZTMzYTdmNWEtMjVkNi00ZDE1LThhOGUtYTYyMzhkOGZiNWRjLTEwNDAzOTMtMjAyNi0wMS0wNi1lbg==/tiny/Outlook-Therapeutics-Inc-.png"/></p>

Outlook Therapeutics 任命 Laura Cantrell 为企业战略和业务发展副总裁 | OTLK 股票新闻